GENOSCIENCE PHARMA
LIVE

Serial Number

79258665

Owner

GENOSCIENCE PHARMA

Attorney

James R. Robinson

Filing Date

Feb 1, 2019

Add to watchlist:

No watchlists yet
View on USPTO

GENOSCIENCE PHARMA Trademark

Serial Number: 79258665 • Registration: 6132420

GENOSCIENCE PHARMA is a trademark filed by GENOSCIENCE PHARMA on February 1, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

GENOSCIENCE PHARMA

10 Rue d'IƩna

Entity Type: 34

Trademark Details

Filing Date

February 1, 2019

Registration Date

August 25, 2020

Published for Opposition

June 9, 2020

Goods & Services

Pharmaceutical preparations, pharmaceutical products, and pharmaceutical substances, namely, pharmaceutical preparations for the treatment of cancer-related diseases or conditions; pharmaceutical preparations for cancer treatment; biopharmaceutical products for cancer treatment, namely, biological preparations for the treatments of cancer; pharmaceutical products for cancer treatment; pharmaceutical preparations and substances for cancer prevention; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for cancer prevention and treatment; biotechnological preparations for medical use, namely, biological tissue cultures for medical purposes; diagnostic agents for medical use; strips for medical diagnosis, namely, medical diagnostic test strips for cancer diagnosis; diagnostic preparations for medical use; diagnostic reagents for medical use; diagnostic substances for medical use; pharmaceutical medicine products and diagnostic products for sample preparation, modification and manipulation of cells and for marking, separation, isolation, reproduction and/or cleaning of biopolymers, nucleic acids, proteins, macromolecules and biologically active substances, namely, chemical reagents for medical purposes

Active chemical ingredients used in the manufacture of anti-cancer drugs; chemical products intended for pharmaceutical sciences, namely, chemical additives for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industry, namely, preservatives for use in the pharmaceutical industry; antioxidants for the manufacture of pharmaceutical products; chemical preparations for be used in the manufacture of pharmaceutical products, namely, active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer-related diseases or conditions; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for industrial use; chemicals used in biotechnological manufacturing processes; diagnostic preparations and diagnostic reagents for scientific or research use; reagents and solvents for sample preparation, modification and manipulation of cells, as well as for the implementation of marking methods, separation, isolation, reproduction and/or cleaning of biopolymers, nucleic acids, proteins, macromolecules, namely, reagents for scientific use and biologically active substances for diagnostic use, namely, biologically active enzymes and microorganisms that are aimed as sanitizing water environments and to treat the activation and optimization of biological filter systems

Medical analysis services for diagnosing cancer; medical analysis of RNA or DNA for cancer diagnosis and prognosis; medical analysis services for cancer diagnosis and prognosis; colorectal cancer screening services; medical services for diagnosing diseases; medical diagnosis of cancer-related diseases or conditions; medical testing for the diagnosis and treatment of persons; medical analysis services for cancer diagnosis; medical testing and analysis for diagnostic or treatment purposes

Development of new technology on behalf of third parties in the field of genetics and biotechnology; biotechnological processes for regulating, modifying and characterizing of disease conditions, medical research specialized in the biotechnological field with respect to regulating, modifying and characterizing diseases or conditions; research and development for third parties in the field of biotechnology; manufacturing and consolidating upon request of DNA, biological organisms, cells, viruses, pathogens, special cells which have been genetically modified according to the specification of third parties for scientific, medical and laboratory use and for research, namely, medical and scientific laboratory services; gene therapy services for third parties, namely, scientific research and product development regarding DNA, biological organisms, cells, viruses, pathogens and special cells which have been genetically modified for scientific and medical use and for research; scientific and technological services, namely, research and design in the field of medical treatment, namely, cancer treatment; industrial analysis and research services, namely, testing, analysis and evaluation of drugs for treatment of cancer and cancer-related diseases and conditions to assure compliance with industry and regulatory standards; research and development of anti-cancer drugs; development of pharmaceutical preparations and medicines; development of pharmaceutical products; development of chemical compounds, namely, custom design and development of reagents and biochemical assays; research and development of new products for others with respect to chemical compounds for therapeutic use; pharmaceutical drug development services for anti-cancer drugs; evaluation of pharmaceutical products; research in the field of pharmaceutical products, namely, pharmaceutical research and development; pharmaceutical research and development in the field of anti-cancer drugs; pharmaceutical research and development services; pharmaceutical research; carrying out clinical trials for pharmaceutical products, namely, conducting clinical trials for others; conducting cancer treatment clinical trials for others; provision of medical and scientific research information concerning the results of clinical trials for pharmaceutical products; laboratory research services in the field of pharmaceuticals; laboratory research services for cancer treatment; testing, inspection and research services in the field of pharmaceuticals; testing, inspection and research for pharmaceuticals for cancer treatment; biotechnological research services; preparation of reports in the field of biotechnology; research and development in the field of biotechnology; services provided by consultants in the field of biotechnology, namely, scientific research consulting in the field of biotechnology; providing scientific research information in the biochemical and biotechnological fields; product design and development in the field of medical and pharmaceutical diagnostic apparatus

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Aug 25, 2025 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 3, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 16, 2020 FICS
FINAL DISPOSITION PROCESSED
Dec 15, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 25, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 25, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 9, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jun 9, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Jun 5, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 20, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 20, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 20, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 4, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 30, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 30, 2020 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 30, 2020 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 13, 2020 GNFN
FINAL REFUSAL E-MAILED
Jan 13, 2020 GNFR
FINAL REFUSAL WRITTEN
Jan 13, 2020 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 18, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 18, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 18, 2019 TROA
REFUSAL PROCESSED BY IB
Jul 12, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 24, 2019 RFCS
REFUSAL PROCESSED BY MPU
Jun 24, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 4, 2019 RFCR
NON-FINAL ACTION WRITTEN
Jun 3, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
May 24, 2019 MAFR
ASSIGNED TO EXAMINER
May 20, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 20, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 16, 2019 REPR